NCI-2021-14403

A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer

This study aims to see if adding a new drug, TRC102, to the standard treatment for stage III non-squamous non-small cell lung cancer (NSCLC) can improve outcomes. TRC102 blocks an enzyme called BER, which cancer cells use to repair their DNA, potentially making cancer cells more sensitive to treatment. Patients diagnosed with stage III non-squamous NSCLC can participate. Participants will be randomly assigned to two groups: one receiving the standard treatment plus TRC102, the other receiving just the standard treatment. Both groups will be closely monitored for treatment response and side effects.

NSCLC: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05198830

Clinical Trial Site: Einstein

To see all available clinical trials click here.